← Back to patent-cliff list
Ibrilatazar
Tier C — Watch / tradeIbrilatazar
Lipopharma Therapeutics Sl
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DHFR, PPARα, PPARγ
Indications (approved)：Pancreatic cancer, Squamous cell carcinoma, Endometrial cancer, Non-small cell lung cancer, Solid tumour
Regional status
US
Phase II
2021-05-06
EU
Phase II
2016-12-01
China
IND filed
2018-10-29
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ibrilatazar?
Approved indications include: Pancreatic cancer, Squamous cell carcinoma, Endometrial cancer, Non-small cell lung cancer, Solid tumour.
When does the Ibrilatazar patent expire?
No public expiry year is available for Ibrilatazar yet; this page updates once verified.
How do I get a quote for Ibrilatazar intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-10